UY36143A - Derivados de pirazolo-pirimidina novedosos - Google Patents

Derivados de pirazolo-pirimidina novedosos

Info

Publication number
UY36143A
UY36143A UY0001036143A UY36143A UY36143A UY 36143 A UY36143 A UY 36143A UY 0001036143 A UY0001036143 A UY 0001036143A UY 36143 A UY36143 A UY 36143A UY 36143 A UY36143 A UY 36143A
Authority
UY
Uruguay
Prior art keywords
pyrimidine derivatives
new
pirazolo
proteolytic
activity
Prior art date
Application number
UY0001036143A
Other languages
English (en)
Inventor
Simic Oliver
Carole Pissot Soldermann
Marina Tintelnot-Blomley
Zoller Thomas
Quancard Jean
Schlapbach Achim
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of UY36143A publication Critical patent/UY36143A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Transplantation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención describe nuevos derivados de pirazolo-pirimidina, los cuales están generalmente interactuando con la actividad proteolítica y auto-proteolítica de MALT1, y en particular que pueden inhibir esa actividad. La presente invención describe además la síntesis de estos nuevos derivados de pirazolo-pirimidina, su uso como un medicame nto, en especial mediante su interacción con la actividad proteolítica y auto-proteolítica de MALT1.
UY0001036143A 2014-05-28 2015-05-28 Derivados de pirazolo-pirimidina novedosos UY36143A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP14170408 2014-05-28

Publications (1)

Publication Number Publication Date
UY36143A true UY36143A (es) 2016-01-08

Family

ID=50828759

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001036143A UY36143A (es) 2014-05-28 2015-05-28 Derivados de pirazolo-pirimidina novedosos

Country Status (36)

Country Link
US (2) US9815842B2 (es)
EP (1) EP3149001B1 (es)
JP (1) JP6545197B2 (es)
KR (1) KR20170007311A (es)
CN (1) CN106170489B (es)
AP (1) AP2016009487A0 (es)
AR (1) AR100645A1 (es)
AU (1) AU2015265478B2 (es)
BR (1) BR112016024545A2 (es)
CA (1) CA2945077A1 (es)
CL (1) CL2016002942A1 (es)
CR (1) CR20160548A (es)
CU (1) CU24393B1 (es)
CY (1) CY1121946T1 (es)
DK (1) DK3149001T3 (es)
EA (1) EA032050B1 (es)
ES (1) ES2738695T3 (es)
GT (1) GT201600249A (es)
HR (1) HRP20191261T1 (es)
HU (1) HUE044351T2 (es)
IL (1) IL247949A0 (es)
LT (1) LT3149001T (es)
MX (1) MX2016015544A (es)
MY (1) MY182487A (es)
PE (1) PE20170189A1 (es)
PH (1) PH12016501862A1 (es)
PL (1) PL3149001T3 (es)
PT (1) PT3149001T (es)
RS (1) RS59039B1 (es)
SG (1) SG11201607895PA (es)
SI (1) SI3149001T1 (es)
SV (1) SV2016005328A (es)
TR (1) TR201910730T4 (es)
TW (1) TWI709561B (es)
UY (1) UY36143A (es)
WO (1) WO2015181747A1 (es)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3113343A1 (en) 2010-06-03 2011-12-08 Pharmacyclics Llc Use of inhibitors of bruton's tyrosine kinase (btk) in the treatment of follicular lymphoma
EP3550031A1 (en) 2012-07-24 2019-10-09 Pharmacyclics, LLC Mutations associated with resistance to inhibitors of bruton's tyrosine kinase (btk)
JP6989505B2 (ja) 2015-08-28 2022-01-05 コーネル ユニヴァーシティー Ｍａｌｔ１阻害剤およびその使用
KR20180080311A (ko) * 2015-11-13 2018-07-11 노파르티스 아게 신규 피라졸로 피리미딘 유도체
TWI726969B (zh) 2016-01-11 2021-05-11 比利時商健生藥品公司 用作雄性激素受體拮抗劑之經取代之硫尿囊素衍生物
CN107296807B (zh) * 2016-04-15 2020-03-20 中国科学院上海生命科学研究院 Malt1靶向抑制物在制备malt1依赖性肿瘤治疗药物中的应用
WO2018019755A1 (en) 2016-07-26 2018-02-01 Basf Se Herbicidal pyridine compounds
WO2018019721A1 (en) 2016-07-26 2018-02-01 Basf Se Herbicidal pyridine compounds
SG11201900745VA (en) * 2016-07-29 2019-02-27 Lupin Ltd Substituted thiazolo-pyridine compounds as malt1 inhibitors
EP3495348A4 (en) 2016-07-29 2020-01-22 Toray Industries, Inc. GUANIDINE DERIVATIVE AND USE THEREOF FOR MEDICAL PURPOSES
RU2021113671A (ru) 2016-07-29 2021-07-08 Люпин Лимитед Замещенные тиазолопиридиновые соединения в качестве ингибиторов malt1
JP7097880B2 (ja) * 2016-11-01 2022-07-08 コーネル ユニバーシティー Ｍａｌｔ１分解のための化合物
TWI795381B (zh) * 2016-12-21 2023-03-11 比利時商健生藥品公司 作為ｍａｌｔ１抑制劑之吡唑衍生物
US10829482B2 (en) 2016-12-27 2020-11-10 Kao Corporation Method for producing glyceric acid ester
WO2018124148A1 (ja) * 2016-12-27 2018-07-05 花王株式会社 グリセリン酸エステルの製造方法
WO2018124147A1 (ja) 2016-12-27 2018-07-05 花王株式会社 １，３－ジオキサン－５－オン類の製造方法
US20200009135A1 (en) 2017-02-01 2020-01-09 Medivir Ab Therapeutic applications of malt1 inhibitors
WO2018159650A1 (ja) * 2017-02-28 2018-09-07 東レ株式会社 グアニジン誘導体及びその医薬用途
WO2018165385A1 (en) 2017-03-08 2018-09-13 Cornell University Inhibitors of malt1 and uses thereof
WO2018226150A1 (en) * 2017-06-05 2018-12-13 Medivir Aktiebolag Pyrazolopyrimidine as malt-1 inhibitors
JP7157738B2 (ja) * 2017-06-08 2022-10-20 三井化学アグロ株式会社 ピリドン化合物およびそれを有効成分とする農園芸用殺菌剤
JP7271540B2 (ja) * 2017-11-17 2023-05-11 へパジーン セラピューティクス （エイチケイ） リミテッド Ａｓｋ１阻害剤としての尿素誘導体
EA202092962A1 (ru) 2018-06-18 2021-09-06 Янссен Фармацевтика Нв Производные пиразола в качестве ингибиторов malt1
JP7296408B2 (ja) * 2018-06-18 2023-06-22 ヤンセン ファーマシューティカ エヌ．ベー． Ｍａｌｔ１阻害剤としてのピラゾール誘導体
CN118420620A (zh) 2018-11-28 2024-08-02 武田药品工业株式会社 杂环化合物
CN109503473B (zh) * 2019-01-07 2020-07-07 上海慧川生物医药科技有限公司 2-甲氧基-3-氨基-5-吡啶硼酸频哪醇酯及其中间体的合成方法
WO2020208222A1 (en) 2019-04-11 2020-10-15 Janssen Pharmaceutica Nv Pyridine rings containing derivatives as malt1 inhibitors
WO2021000855A1 (en) * 2019-07-01 2021-01-07 Qilu Regor Therapeutics Inc. Malt1 inhibitors and uses thereof
CN111138437B (zh) * 2019-12-04 2021-03-05 杭州华东医药集团新药研究院有限公司 取代的吡唑并[1,5-a]嘧啶氨基酸衍生物及其用途
EP4163280A4 (en) 2020-05-27 2024-06-05 Takeda Pharmaceutical Company Limited METHOD FOR PREPARING A HETEROCYCLIC COMPOUND
US20230235077A1 (en) 2020-06-24 2023-07-27 The General Hospital Corporation Materials and methods of treating cancer
TW202220992A (zh) * 2020-08-05 2022-06-01 匈牙利商羅特格登公司 具藥理活性之經雜環取代的吡唑并〔１，５－ａ〕嘧啶衍生物
AU2021361057A1 (en) * 2020-10-16 2023-06-08 Rarefied Biosciences, Inc. Malt1 modulators and uses thereof
CN116710089A (zh) * 2020-11-12 2023-09-05 莫诺泰罗斯疗法公司 治疗癌症的材料和方法
GB202018412D0 (en) 2020-11-23 2021-01-06 Exscientia Ltd Malt-1 modulators ii
AU2022425324A1 (en) 2021-12-30 2024-05-30 Jiangsu Hansoh Pharmaceutical Group Co., Ltd. Tricyclic derivative inhibitor, preparation method therefor, and application thereof
CN118591541A (zh) * 2022-01-18 2024-09-03 奥瑞基尼肿瘤有限公司 作为malt-1抑制剂的经取代的双环杂环
CN116535424A (zh) * 2022-01-26 2023-08-04 武汉誉祥医药科技有限公司 作为malt1抑制剂的三并环化合物及其药物组合物和应用
CN118525021A (zh) * 2022-01-28 2024-08-20 上海齐鲁制药研究中心有限公司 靶向malt1的蛋白降解化合物
TW202342032A (zh) 2022-02-02 2023-11-01 日商小野藥品工業股份有限公司 含有ｍａｌｔ１抑制劑作為有效成分的癌治療劑
WO2023148501A1 (en) 2022-02-03 2023-08-10 C4X Discovery Limited Heterocyclic derivatives as malt1 inhibitors

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7517880B2 (en) 1997-12-22 2009-04-14 Bayer Pharmaceuticals Corporation Inhibition of p38 kinase using symmetrical and unsymmetrical diphenyl ureas
US20020065296A1 (en) 1999-01-13 2002-05-30 Bayer Corporation Heteroaryl ureas containing nitrogen hetero-atoms as p38 kinase inhibitors
DK1478358T3 (da) 2002-02-11 2013-10-07 Bayer Healthcare Llc Sorafenibtosylat til behandling af sygdomme kendetegnet ved unormal angiogenese
WO2003091256A1 (fr) * 2002-04-23 2003-11-06 Shionogi & Co., Ltd. Derive de pyrazolo[1,5-a]pyrimidine et inhibiteur de la nad(p)h oxydase contenant ledit derive
CA2487211C (en) 2002-06-04 2010-09-14 Neogenesis Pharmaceuticals, Inc. Pyrazolo(1,5a) pyrimidine compounds as antiviral agents
KR20050057072A (ko) 2002-09-04 2005-06-16 쉐링 코포레이션 사이클린 의존성 키나제 억제제로서의 피라졸로피리미딘
JP2007524596A (ja) 2003-02-28 2007-08-30 トランスフォーム・ファーマシューティカルズ・インコーポレイテッド 共結晶医薬組成物
ES2393741T3 (es) * 2005-01-14 2012-12-27 Gilead Connecticut, Inc. Ureas 1,3-diarilsustituidas como moduladores de la actividad quinasa
WO2008063671A2 (en) * 2006-11-20 2008-05-29 Alantos Pharmaceuticals Holding, Inc. Heterobicyclic metalloprotease inhibitors
ATE553769T1 (de) 2007-11-21 2012-05-15 Vib Vzw Inhibitoren der malt1-proteolytischen aktivität und ihre verwendung
GB0821307D0 (en) 2008-11-21 2008-12-31 Summit Corp Plc Compounds for treatment of duchenne muscular dystrophy
AR077468A1 (es) 2009-07-09 2011-08-31 Array Biopharma Inc Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa
KR101851130B1 (ko) * 2009-12-04 2018-04-23 센화 바이오사이언시즈 인코포레이티드 Ｃｋ2 억제제로서 피라졸로피리미딘 및 관련된 헤테로사이클
US8883801B2 (en) 2010-08-23 2014-11-11 Merck Sharp & Dohme Corp. Substituted pyrazolo[1,5-a]pyrimidines as mTOR inhibitors
EP2465928A1 (en) 2010-12-16 2012-06-20 Academisch Medisch Centrum bij de Universiteit van Amsterdam Treatment of Th17-mediated diseases
WO2013028263A1 (en) * 2011-08-24 2013-02-28 Glaxosmithkline Llc Pyrazolopyrimidine derivatives as pi3 kinase inhibitors
CN103570723B (zh) * 2012-07-27 2016-07-13 广西梧州制药（集团）股份有限公司 吡唑并嘧啶衍生物及其制备方法和在药物制备中的用途
US9822118B2 (en) * 2012-11-13 2017-11-21 Array Biopharma Inc. Bicyclic heteroaryl urea, thiourea, guanidine and cyanoguanidine compounds as TrkA kinase inhibitors
WO2014100620A2 (en) 2012-12-21 2014-06-26 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
WO2014181287A1 (en) 2013-05-09 2014-11-13 Piramal Enterprises Limited Heterocyclyl compounds and uses thereof
CN103739550B (zh) * 2014-01-02 2016-06-01 中国药科大学 2,3-二甲基-6-脲-2h-吲唑类化合物及其制备方法与应用

Also Published As

Publication number Publication date
GT201600249A (es) 2018-12-18
SG11201607895PA (en) 2016-12-29
EA201692105A1 (ru) 2017-04-28
CR20160548A (es) 2017-01-02
IL247949A0 (en) 2016-11-30
EP3149001A1 (en) 2017-04-05
US10442808B2 (en) 2019-10-15
CN106170489A (zh) 2016-11-30
MX2016015544A (es) 2017-03-23
DK3149001T3 (da) 2019-07-22
PE20170189A1 (es) 2017-03-15
JP2017516778A (ja) 2017-06-22
WO2015181747A1 (en) 2015-12-03
HUE044351T2 (hu) 2019-10-28
US9815842B2 (en) 2017-11-14
AP2016009487A0 (en) 2016-10-31
AU2015265478B2 (en) 2017-09-14
PT3149001T (pt) 2019-07-25
EA032050B1 (ru) 2019-03-29
MY182487A (en) 2021-01-25
PL3149001T3 (pl) 2019-10-31
TR201910730T4 (tr) 2019-08-21
TWI709561B (zh) 2020-11-11
CL2016002942A1 (es) 2017-07-14
CA2945077A1 (en) 2015-12-03
LT3149001T (lt) 2019-08-12
CU20160181A7 (es) 2017-05-10
TW201609740A (zh) 2016-03-16
JP6545197B2 (ja) 2019-07-17
US20170121335A1 (en) 2017-05-04
RS59039B1 (sr) 2019-08-30
SI3149001T1 (sl) 2019-08-30
CY1121946T1 (el) 2020-10-14
PH12016501862B1 (en) 2016-12-19
ES2738695T3 (es) 2020-01-24
CU24393B1 (es) 2019-04-04
EP3149001B1 (en) 2019-04-24
AR100645A1 (es) 2016-10-19
PH12016501862A1 (en) 2016-12-19
US20180030061A1 (en) 2018-02-01
CN106170489B (zh) 2019-05-03
SV2016005328A (es) 2018-06-12
AU2015265478A1 (en) 2016-10-20
BR112016024545A2 (pt) 2017-08-15
KR20170007311A (ko) 2017-01-18
HRP20191261T1 (hr) 2019-10-04

Similar Documents

Publication Publication Date Title
UY36143A (es) Derivados de pirazolo-pirimidina novedosos
PH12018500932A1 (en) Novel pyrazolo pyrimidine derivatives
ECSP17018120A (es) Triazolopirazinonas como inhibidores de pde1
CO2017001994A2 (es) Compuestos activos hacia bromodominios
CL2016002681A1 (es) 1h-pirrolo[2,3-c]piridin-7(6h)-onas y pirazolo[3,4-c]piridin-7(6h)-onas como inhibidores de proteínas bet.
CL2015001377A1 (es) Inhbibidores de bmi-1 primidinas sustituidas inversas
CL2014001793A1 (es) Compuestos derivados de 1,3,5-triazinas sustituidas y sus sales, como inhibidores de la idh2 mutante; composicion farmaceutica que los comprende; y su uso para el tratamiento del cancer.
CR20160553A (es) Procesos para preparar un inhibidor de jak1 y nuevas formas de este
CL2015002891A1 (es) Deaza-purinonas macrocíclicas para el tratamiento de infecciones virales.
CL2016002346A1 (es) Composiciones para modular la expresión de ataxina 2
CL2015002060A1 (es) Compuestos.
CL2017002719A1 (es) Imidazopirazinonas como inhibidores de pde1
UY36224A (es) Compuestos tricíclicos de imidazo-pirimidinona
CL2016002207A1 (es) Compuestos derivados de 1,2-dihidro-3h-pirrolo[1,2-c]imidazol-3-ona, con actividad antibacteriana gram (+) y gram (-); composicion farmacéutica que los comprende.
CL2016001349A1 (es) Uso de derivados de bencimidazol-prolina
AR093939A1 (es) Composiciones que comprenden vortioxetina y donepezil
CR20160316A (es) Compuestos derivados de hidroxiformamida y usos del mismo
CL2016002779A1 (es) Composición para el cuidado de la piel
CR20170090A (es) Derivados de terahidroquinolina como inhibidores del bromodominio
ECSP16061208A (es) Quinazolin-thf-aminas como inhibidores de pde1
DOP2016000263A (es) Quinazolin-thf-aminas halogenadas como inhibidores de pde1
PH12016502311A1 (en) Omega-3 analogues
BR112017007753A2 (pt) uso de uma composição cosmética que compreende ácido 10-hidroxiesteárico.
ECSP16071574A (es) Hexahidrofuropirroles como inhibidores de pde1
EA201790526A1 (ru) Фармацевтические комбинации ситаглиптина

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20220620